Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$17.44 USD
+0.58 (3.44%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $17.42 -0.02 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Viridian Therapeutics, Inc. has a market cap of $1.38B, which represents its share price of $16.86 multiplied by its outstanding shares number of 81.59M. As a small-cap company, VRDN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VRDN 17.44 +0.58(3.44%)
Will VRDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
Other News for VRDN
Viridian (VRDN) Reports Strong Q2 Revenue and Strategic Advances
Viridian Therapeutics GAAP EPS of -$1.00 beats by $0.03, revenue of $0.08M beats by $0.03M
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial ...
Viridian Therapeutics reports Q2 EPS ($1.00), consensus (97c)
Viridian Therapeutics Announces Inducement Grants for New Employees | VRDN stock news